Pharmaceutical Executive-08-01-2005

Pharmaceutical Executive

40-a-day

August 01, 2005

From the Editor

0

0

With patients who suffer from poverty, lack of education, and disease, it is incredibly easy to do damage through a marketing tactic that might be acceptable for another group.

Washington Report: Treating Patents

August 01, 2005

Washington Report

0

0

Integra v. Merck KGaA supports research by large pharmaceutical companies, but it also opens the door to greater use of compounded materials by all parties. Congress may have to clarify its scope.

Backpage: Feet-on-the-Street Interview

August 01, 2005

Columns

0

0

The rep's job is getting tougher. That's the major takeaway from a recent survey of reps conducted by Epocrates. The company interviewed 300 randomly selected reps who had purchased at least one Epocrates product license certificate, asking them how their jobs had changed in the past three years.

Global Report: Big Disadvantage

August 01, 2005

Global Report

0

0

SPCs extend a drug's basic patent protection for up to five years, to take into account the time that may have lapsed between the filing of a patent application and the granting of market authorization.

Part D Phase 2

August 01, 2005

Features

0

0

Manufacturers will have to incorporate Part D–specific messaging into all of their current marketing materials. In addition, they should consider publication plans and CME that specifically address the needs of seniors.

Marketing to Professionals: Penetrating P&T

August 01, 2005

Columns

0

0

As a result of the rapid innovations in drug technology, and the increasing complexities surrounding drugs' safety, cost, and efficacy, the demand for extensive formulary reviews is growing. To keep pace, Pharmacy & Therapeutics (P&T) committees have been ardently reviewing medications to determine which ones deserve inclusion and preferred placements in health plans and formularies. While there are many factors that influence the committees' decisions, with some carrying more weight than others, pharmaceutical execs complain that there is no accurate way to predict which drugs will make the cut.